Issue 9 | Fall 2020

**CANREVALUE GOES VIRTUAL**

Due to the global pandemic, our planned in-person meeting this May was cancelled. Our innovative events team stepped to the plate, and on August 13th, 2020, we held our first virtual CanREValue meeting with grant members and participants from the Policy Working Groups (Planning and Drug Selection WG and Reassessment & Uptake WG). The objective of the virtual meeting was to update participants on the current draft of the CanREValue framework and to discuss potential facilitators, barriers, strategies, readiness and next steps in incorporating the framework. With both large group and breakout sessions, we are very proud of the meaningful and thoughtful discussions that took place, and we thank all members who were able to participate and provided feedback making the event a success!

Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information.

**CANREVALUE STAKEHOLDER CONSULTATIONS**

We are pleased that the public stakeholder consultations regarding the Interim Policy Report developed by the CanREValue Policy Working Groups is now complete.

We received feedback from 21 diverse stakeholders. After carefully considering the feedback, we have developed a response document which is available on our website by clicking here.

As a reminder, all CanREValue reports and updates are publicly posted on our website at https://cc-arcc.ca/canrevalue-kt/.

Follow us on Twitter @CanREValue
**Coming Soon:** Our team is currently working on reviewing feedback received for the Interim Method Working Group Report and drafting our response document. We expect to post a feedback response document in December of 2020 – keep an eye on our website.

Please e-mail us at CanREValue@cc-arcc.ca if you have any questions or need additional information.

**WORKING GROUP UPDATES AND NEXT STEPS:**

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Updates &amp; Next Steps</th>
</tr>
</thead>
</table>
| RWE Planning and Drug Selection | **Updates:**
  - The Interim Policy Working Group Response to Stakeholder Consultation is now available on the CanREValue website [Click Here to Access](#)  
**Next Steps:**
  - Developing MCDA Workshops to be held in the coming months |
| RWE Data | **Updates:**
  - Held 2 interprovincial analysis meetings to present preliminary cohort characteristics from NL and ON  
  - Developed CADTH presentations on the work of the Data WG  
**Next Steps:**
  - Continue with real-world analysis (cohort creation and comparative effectiveness) in 9 provinces |
| RWE Methods | **Updates:**
  - Reviewing and responding to feedback from stakeholder consultation  
**Next Steps:**
  - Finalize response document and post online |
| RWE Reassessment and Uptake | **Updates:**
  - The Interim Policy Working Group Response to Stakeholder Consultation is now available on the CanREValue website [Click Here to Access](#)  
  - WG teleconference has been scheduled for Monday November 30th and Tuesday December 8th (Note: content in both teleconferences are identical)  
**Next Steps:**
  - WG Members will be participating in a teleconference later this month to further develop and refine Step 4 of the CanREValue Framework and the RWE Implementation Plan. |
| Stakeholder Engagement | **Updates:**
  - Planning upcoming industry engagement activities, discussion with JOPT scheduled for December 2nd, 2020.  
  - Disseminated and promoted uptake of the Policy Working Group Response to Stakeholder Consultation documentation  
**Next Steps:**
  - Disseminate and promote response to the Interim Method Working Group Report once available |
CANREVALUE CORE RESEARCH TEAM UPDATE – WELCOME AND CONGRATULATIONS

WELCOME TO OUR NEW MEMBERS
We would like to welcome Dr. Avram Denburg as a CanREValue Co-Investigator and a member of the CanREValue Core Team! Dr. Denburg is a pediatric oncologist from SickKids hospital. He has expertise in cancer policy and HTA research and will continue to work within our core team as the primary liaison with the CanREValue Policy Working Groups.

We would like to officially welcome Ms. Gunita Mitera as a formal CanREValue collaborator. As the Executive Director for CAPCA, Ms. Mitera brings an extremely valuable perspective to the CanREValue table, and we are grateful for her ongoing support!

We are pleased to announce the promotion of Ms. Suzanne McGurn to be our Principal Knowledge User (PKU). As many of you know, our initial PKU, Dr. Michael Sherar transitioned from his role with Cancer Care Ontario, and Ms. McGurn has recently begun her role as President & CEO of CADTH. She has been part of the CanREValue team since day 1, and we are especially excited to be able to have her step into this important role.

Finally, we are excited to introduce you to our new Project Manager, Ms. Pam Takhar. Pam has seamlessly integrated into the CanREValue team, and you can find out more about her below in the member spotlight section – Welcome Pam!

CONGRATULATIONS WEI FANG DAI
We are excited to announce that Wei has been accepted into Medical School at the University of Toronto as part of the class of 2024. We thank Wei for her dedication to the CanREValue Collaboration and wish her all the best as she embarks on this exciting next chapter! Wei will remain engaged as part of the CanREValue team and Data Working Group during her studies.

CONGRATULATIONS DR. KELVIN CHAN
On November 9th, 2020 CanREValue PI Dr. Kelvin Chan was presented with the 2020 Dr. Maurice McGregor Award at the 2020 CADTH Conference. This award recognizes rising HTA stars early in their careers, and is given to nominees who have demonstrated excellence in the production, promotion, or use of HTA in Canada, as well as the potential to be leaders in the field as their career develops. Congratulations Kelvin!
MEMBER SPOTLIGHT – PAM TAKHAR, SR RESEARCH ASSOCIATE

Pam has recently joined the CanREValue Core Team to assist with the overall project management of the CanREValue Collaboration.

Q: What is your educational background and research interests?
After completing my BPHE at the University of Toronto, I went on to pursue my Kinesiologist designation and completed a MSc in Evidence Based Healthcare (EBH) & HTA.

My research interests are in health services research, health technology assessment and rehabilitative sciences. At Ontario Health, I am a Sr. Research Associate with the Evidence Search and Review Services unit where I support programs across the organization in making evidence-informed decisions in topics relating to health policy and quality improvements.

I am grateful for the opportunity to work with the CanREValue Collaboration and look forward to working with you all!

Q: What aspect of the CanREValue project are you the most excited to work on?
There are a lot of interesting aspects to this project – I am looking forward to learning more about RWE and HTA in Canada.

Q: What has been the most interesting aspect of this project for you so far?
Although, I was unable to meet the working group members in person, being able to participate in the first ever virtual CanREValue meeting was a great experience. Being relatively new to the project, it was fascinating to dive right in and learn about the framework from various perspectives. It was definitely an informative and enriching experience. Not to mention, I was quite fascinated with the technology behind the breakout groups!

Q: How can we reach you? Feel free to e-mail me at pam.takhar@ontariohealth.ca

Recent Publications/Presentations:

Presentations

Presentations <con’t>

Kelvin Chan, on behalf of the CanREValue RWE Data Working Group, Mapping Canadian Data Assets to conduct Real-world Studies: Lessons learned from CanREValue RWE Data Working Group. 2020 CADTH Symposium (On-demand presentation), November 9th-10th, 2020.


Publications:

CanREValue Core Publication:


Other Publications:

Parmar A, Chan KKW. Prioritising research into cancer treatment delays. BMJ. 2020 Nov 4;371:m4261. doi: 10.1136/bmj.m4261. PMID: 33148613.